Announcing the TTS 2022 “Living Legends” Award Recipients

In recognition of members who have contributed significantly to the field, this year TTS is recognizing as “Living Legends” members with extraordinary reputations that have contributed tremendously to the field either through research, innovation or mentorship.

International

David K.C. Cooper
USA
Rafael Matesanz
Spain
Randall E. Morris
USA

Latin America

Josefina Alberú
Mexico
Eduardo Santiago-Delpin
Puerto Rico
Federico Villamil
Argentina

Argentina

Domingo Casadei
Argentina
Eduardo de Santibañes
Argentina
Félix Cantarovich
Argentina

TTS 2022 starts in one week!

You can now browse the detailed program and see who is presenting at TTS 2022. If you plan to attend virtually you can view the schedule in your local time zone.

Register to the Congress

Online In-Person registration is closed (You can still register in-person onsite from 2-6 pm on September 10 or after 7 am on September 11).


Virtual Registration will remain open during the entire duration of the congress.


Hotel reservations are available here - Book early as space is limited!

Transplantation Updates

Transplantation - September Issue

Transplantation - Week's Most Downloaded Paper

Moving Toward Transplant Tolerance: Is Targeting Donor Antigen-presenting Cells the Key?

Donor-specific tolerance is a long-held, elusive goal for transplantation. While robust dominant tolerance across major histocompatibility complex (MHC) barriers has been achieved by numerous manipulations in rodents, translation into nonhuman primate (NHP) models or clinical practice has been challenging. Apart from the induction of hematopoietic chimerism there are very few examples of allograft tolerance in clinical practice. Whether persistent chimerism (versus that of a transient nature) is an absolute requirement for tolerance has been debated, however without resolution. Furthermore, the induction of chimerism requires extensive preconditioning and is associated with significant toxicity, particularly graft versus host disease, factors which have limited its clinical feasibility.

Transplantation Direct - Highlighted Tweet

The Role of Donor Sex in Females Undergoing Repeat Kidney Transplant: Does Prior Donor Sex Matter?

Female recipients of male donor kidneys are at increased risk for graft failure because of the HY antigen effect. However, whether prior transplant with a male donor impacts subsequent transplant outcomes is unknown. Therefore, the purpose of this study was to determine whether prior male-current male donor sex is associated with an increased risk of graft failure in female recipients.

TTS Education Committee - DIGC Pre-Congress Session at TTS 2022 Buenos Aires


TTC Public Workshop - September 22, 2022 @ 8AM ET

Since 2017 TTS has been participating in the Transplantation Therapeutics Consortium (TTC), a program of the Critical Path Institute.

Accelerating medical product development in kidney transplantation through a public-private partnership

This public workshop will focus on 1) qualifying a composite surrogate for long-term graft loss after kidney transplantation 2) real-world evidence (RWE) use in transplant clinical trials and 3) potential future endpoints in kidney transplantation The Transplant Therapeutics Consortium (TTC) aims to accelerate the medical product development process for transplantation by identifying challenges, prioritizing solutions, and developing tools to advance new product development to meet the most pressing needs of transplant recipients.
Click to view the agenda
Welcoming remarks
Session 1: Qualifying a composite surrogate for long-term graft loss after kidney transplantation
  • Regulatory qualification procedures and qualification status of the iBox Scoring System as a reasonably likely surrogate endpoint with FDA
  • Graphical user interface for sample size calculation using iBox scores
  • Panel discussion
Session 2: RWE use in transplant clinical trials
  • Regulatory and design considerations for RWE supplementation in transplant clinical trials
  • Pilot study for external control using the cyclosporine arm of the BENEFIT RCT versus UNOS/OPTN registry data
  • Sample size calculation and use RWE for supplemental external controls for the 5-year survival analyses
  • Panel discussion
Session 3: Future endpoints in kidney transplantation
  • Efficacy endpoints
  • Safety endpoints
  • Regulatory qualification procedures for clinical outcome assessments
  • Patient-reported outcome measures for transplantation
  • Panel discussion
Closing Remarks

Upcoming Webinar: TID - Clinicopathologic Conference Series Continues!


TTS Needs Assessment Survey

This survey focuses on issues encountered by physicians in day-to-day decision-making.

Your responses will aid TTS in developing strategies, programs and resources to improve access and transparency in transplantation, emphasizing increasing deceased donor organ transplantation.

The information collected will also aid the work TTS is doing as part of our World Health Organization collaboration.

All responses will be kept confidential and anonymous.

The survey will take 6+ minutes and must be done from a computer or tablet.

In the News 


Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada